No Data
No Data
Insider Sale: CFO Jane Henderson Sells 6,000 Shares of Apogee Therapeutics Inc (APGE)
Express News | Apogree Therapeutics Shares Are Trading Higher After the Company Announced Its Initiated Dosing of Its Clinical Trail for APG990
Express News | Apogee Therapeutics Has Initiated Dosing Of Healthy Volunteers In Its First Clinical Trial For APG990, A Novel, Subcutaneous Half-life Extended Monoclonal Antibody Targeting OX40L, Which Is Being Developed Initially For Atopic Dermatitis
Express News | Apogee Therapeutics Inc - to Initiate Apg777 and Apg990 Trial in 2025
Express News | Apogee Therapeutics Inc - Expects Apg990 Interim Data in 2025
Express News | Apogee Therapeutics Announces First Participants Dosed in Phase 1 Clinical Trial of Apg990, Its Novel Half-Life Extended Ox40L Antibody for the Treatment of Atopic Dermatitis and Other Inflammatory Diseases